Electromed, Inc. ELMD
Electromed, Inc. ("we," "our," "us," "Electromed" or the "Company") develops, manufactures, markets and sells innovative products that provide airway clearance therapy, including the SmartVest® Airway Clearance System ("SmartVest System") to patients with compromised pulmonary function with a commitment to excellence and compassionate service. Our goal is to make High Frequency Chest Wall Oscillation ("HFCWO") treatments as effective, convenient, and comfortable as possible, so our patients can breathe easier and live better with improved respiratory function and fewer exacerbations.
We primarily employ a direct-to-patient and provider model, through which we obtain patient referrals from clinicians, manage insurance claims on behalf of our patients, and deliver the SmartVest System to patients, training them on proper use in their homes. This model allows us to directly approach patients and clinicians, whereby we disintermediate the traditional home medical equipment ("HME") channel and capture both the manufacturer and distributor margins. We also sell our products in the acute care setting for patients in a post-surgical or intensive care unit, or who were admitted for a lung infection brought on by compromised airway clearance. Electromed was incorporated in Minnesota in 1992. Our common stock is listed on the NYSE American under the ticker symbol "ELMD."
Valuation FY2026 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $73.8M | $64.0M | $54.7M | $48.1M | $41.7M | $35.8M | $32.5M | $31.3M | $28.3M | $25.9M |
| Cost of revenue | $15.8M | $14.0M | $13.0M | $11.5M | $10.2M | $8.5M | $7.3M | $7.5M | $6.5M | $5.3M |
| Gross profit | $57.9M | $50.0M | $41.7M | $36.5M | $31.4M | $27.3M | $25.2M | $23.8M | $21.8M | $20.6M |
| R&D | $1.3M | $996.0K | $656.0K | $916.0K | $1.4M | $1.7M | $1.1M | $583.3K | $251.4K | $596.9K |
| SG&A | $42.7M | $39.3M | $34.5M | $31.6M | $27.1M | $22.4M | $19.9M | $20.4M | $18.8M | $16.4M |
| Total operating expenses | $44.1M | $40.3M | $35.1M | $32.5M | $28.5M | $24.2M | $20.1M | $21.0M | $19.1M | $17.0M |
| Operating income | $13.9M | $9.7M | $6.6M | $4.0M | $3.0M | $3.1M | $5.1M | $2.8M | $2.7M | $3.6M |
| Interest expense | — | — | $455.0K | $78.0K | $25.0K | $27.0K | $121.0K | $90.7K | $19.9K | $49.9K |
| Pre-tax income | $14.4M | $10.3M | $7.0M | $4.1M | $3.0M | $3.2M | $5.2M | $2.9M | $2.7M | $3.5M |
| Income tax | $3.1M | $2.7M | $1.9M | $920.0K | $692.0K | $805.0K | $1.1M | $940.0K | $901.0K | $1.3M |
| Net income | $11.3M | $7.5M | $5.2M | $3.2M | $2.3M | $2.4M | $4.2M | $2.0M | $1.8M | $2.2M |
| EPS, basic | 1.37 | 0.89 | 0.60 | 0.37 | 0.27 | 0.28 | 0.50 | 0.24 | 0.22 | 0.27 |
| EPS, diluted | 1.30 | 0.85 | 0.58 | 0.36 | 0.26 | 0.27 | 0.47 | 0.23 | 0.21 | 0.26 |
| Shares, diluted (wtd. avg.) | $8.7M | $8.9M | $8.9M | $8.7M | $8.8M | $8.9M | $8.8M | $8.6M | $8.6M | $8.5M |
Balance sheet
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $20.4M | $15.3M | $16.1M | $7.4M | $8.2M | $11.9M | $10.5M | — | — | — |
| Receivables | $29.8M | $24.7M | $23.3M | $24.1M | $21.1M | $17.0M | $12.9M | $12.8M | $11.8M | $9.9M |
| Inventory | $3.7M | $3.3M | $3.7M | $4.2M | $3.2M | $2.1M | $3.1M | $2.6M | $2.5M | $2.6M |
| Total current assets | $57.4M | $45.1M | $44.2M | $37.8M | $34.5M | $31.7M | $28.0M | $24.5M | $23.3M | $18.5M |
| Property, plant and equipment | $5.2M | $4.7M | $5.2M | $5.7M | $4.6M | $3.6M | $3.8M | $3.6M | $3.1M | $3.3M |
| Other intangibles | $379.0K | $371.0K | $657.0K | $605.0K | $599.0K | $663.0K | $598.0K | $581.0K | $649.0K | $721.0K |
| Total assets | $66.3M | $53.8M | $52.2M | $45.8M | $41.4M | $37.1M | $33.2M | $29.4M | $27.4M | $23.1M |
| Accounts payable | $2.6M | $2.7M | $1.0M | $1.4M | $1.3M | $685.0K | $556.0K | $586.6K | $810.6K | $663.4K |
| Short-term debt | — | — | — | — | — | $33.0K | $72.0K | $30.3K | $1.1M | $50.7K |
| Total current liabilities | $12.2M | $10.5M | $7.7M | $8.1M | $7.2M | $4.6M | $3.0M | $3.7M | $4.8M | $2.9M |
| Long-term debt | — | — | — | — | — | — | — | — | — | $1.1M |
| Total liabilities | $12.3M | $10.6M | $7.7M | $8.1M | $7.2M | $4.7M | $3.0M | $3.7M | $4.7M | $4.0M |
| Retained earnings | $28.6M | $21.2M | $23.7M | $18.8M | $15.8M | $14.9M | $13.7M | $9.5M | $7.6M | $5.0M |
| Total equity | $54.0M | $43.2M | $44.5M | $37.7M | $34.2M | $32.4M | $30.2M | $25.7M | $22.6M | $19.8M |
Cash flow
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $9.7M | $11.4M | $9.1M | $1.3M | -$686.0K | $3.1M | $4.2M | $2.6M | $2.4M | $1.2M |
| Depreciation and amortisation | $868.0K | $1.0M | $789.0K | $550.0K | $503.0K | $477.0K | $619.0K | $804.6K | $676.4K | $636.7K |
| Stock-based compensation | $2.7M | $3.1M | $1.7M | $708.0K | $976.0K | $1.0M | $902.0K | $924.1K | $862.7K | $479.5K |
| Capital expenditure | $1.3M | $262.0K | $287.0K | $1.6M | $1.4M | $287.0K | $844.0K | $1.3M | $526.2K | $618.8K |
| Investing cash flow | -$1.3M | -$306.0K | -$395.0K | -$1.7M | -$1.5M | -$448.0K | -$977.0K | -$1.4M | -$571.8K | -$687.1K |
| Financing cash flow | -$3.2M | -$11.9M | $36.0K | -$380.0K | -$1.5M | -$1.2M | -$548.0K | -$851.2K | $11.7K | -$53.6K |
| Buybacks | $3.9M | $10.0M | $275.0K | $153.0K | $1.4M | $1.1M | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-028914.
Others in SIC 3845
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| MDT | Medtronic plc | $120.46B | 25.2x | 8.4% |
| LIVN | LivaNova PLC | $4.51B | — | 10.7% |
| ITGR | Integer Holdings Corp | $4.30B | 43.8x | 8.0% |
| TMDX | TransMedics Group, Inc. | $3.12B | 18.5x | 37.1% |
| AXGN | Axogen, Inc. | $2.60B | — | 20.2% |
| BLFS | BIOLIFE SOLUTIONS INC | $1.72B | — | 28.9% |
| CNMD | CONMED Corp | $1.48B | 32.7x | 5.2% |
| CBLL | Ceribell, Inc. | $948.7M | — | 36.1% |